December 2021
-
Novel RET Inhibitors Promising in Chinese Patients with RET-fusion Positive NSCLC
The results of two studies presented at the 2021 World Conference on Lung Cancer—LIBRETTO-321 and ARROW—indicate that the selective RET inhibitors selpercatinib and pralsetinib are promising treatment options for patients […]
-
Second-Line Platinum-Doublet Regimens Reasonable in SCLC
Use of platinum-doublet chemotherapy regimen as second-line treatment for patients with relapsed small-cell lung cancer (SCLC) was a reasonable option compared with nonplatinum-based regimens, according to data from a meta-analysis […]
-
Multifaceted Initiative Launches Aimed at Reducing Lung Cancer Deaths 25% by 2030
The Baptist Cancer Center in Memphis, Tennessee, has launched a new initiative that comprises seven components that will address prevention, diagnosis, and treatment of lung cancer through smoking cessation, low-dose […]
-
Increasing Adherence to CT Lung Cancer Screening Programs
Two large-scale, randomized controlled trials—the U.S. National Lung Screening Trial (NLST; n = 53,454) and the Dutch–Belgian Randomized Lung Cancer Screening Trial (NELSON; n = 15,792)—have demonstrated that lung cancer […]
-
COVID-19 and Lung Cancer
Data from multiple groups1,2 have shown the significant impact of COVID-19 infection among patients with malignancies, leading to high overall morbidity and mortality; this includes our own institution,3 which saw […]
-
Determining Adjuvant Therapy Through Recurrence Prediction: New Investigations
Amid growing interest in validating relapse-prediction models, team links high-grade histology, even if not predominant, with worse outcomes in EGFR-mutated stage 1 NSCLC.
View ILCN Archives
Provider Resources